Industry News
– Israel Institute for Biological Research files initial scientific results of BriLife vaccine effectiveness in producing neutralizing antibody against Omicron Variant – Neutralizing antibody level against Omicron is approximately 1/3 of the comparable antibody level against the original Corona Virus – Ten of 13 tested patients vaccinated during phase 2 trials demonstrated measurable level of…
Read More
Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of BTX-1188 in Patients with Advanced Hematologic and Solid Tumor Malignancies Excerpt from the Press Release: SAN DIEGO, Jan. 26, 2022 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on developing targeted protein degraders to create life-saving medicines, today announced dosing of the first patient in a new, first-in…
Read More
– If successful, BridgeBio’s investigational gene therapy BBP-631 would be the first therapy for CAH to restore the body’s hormone and steroid balance by enabling people with CAH to make their own cortisol and aldosterone -Initial Phase 1/2 data readout anticipated in the second half of 2022 -BridgeBio’s gene therapy portfolio also includes a clinical stage…
Read More
EBT-101 is a CRISPR-based therapeutic being developed as a potential functional cure for people living with HIV First-in-human trial is now open for enrollment Excerpt from the Press Release: SAN FRANCISCO, Jan. 27, 2022 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced…
Read More
Funding from the Bill & Melinda Gates Foundation will support the development of Aridis’ inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19 Excerpt from the Press Release: OS GATOS, Calif., Jan. 27, 2022 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat…
Read More
Enrollment in the first dose escalation is complete with no safety issues reported to date Trial is designed to accelerate pelareorep’s development in Asian territories such as China, the world’s second-largest pharmaceutical market Excerpt from the Press Release: SAN DIEGO, Calif. and CALGARY, AB, Jan. 27, 2022 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye…
Read More
Excerpt from the Press Release: Study met primary endpoint with 47.4% objective response rate Safety and tolerability profile consistent with previously reported data Planned BLA submission on track for later this year Conference call to be held today, Tuesday, January 25, 2022, at 8:30 AM ET WALTHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) — Checkpoint…
Read More
Excerpt from the Press Release: STI-1558, a novel oral Mpro inhibitor, effectively inhibits Omicron virus entry and replication in cells. STI-1558 is orally bioavailable with improved human liver microsomal stability to avoid using Ritonavir as a pharmacokinetic enhancer in humans. SAN DIEGO, Jan. 28, 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today…
Read More
Study to evaluate safety, tolerability, pharmacokinetics, and potential to improve cognition Excerpt from the Press Release: CAMBRIDGE, Mass., Jan. 26, 2022 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that patient dosing has begun in its Phase 2a study…
Read More First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two trials in progress posters presentations for the DEDUCTIVE HCC study and the recently initiated Phase 1b/2 IMMCO-1 study of tivozanib and atezolizumab in multiple immunologically cold tumors Excerpt from the Press Release:…
Read More